Abstract
Regulatory T (Treg) cells play an important role in the maintenance of self-tolerance and are involved in the prevention of autoimmune diseases and reduce/inhibit the progression of chronic inflammatory diseases. Forkhead box P3 (FoxP3) expression in Treg cells is believed to be a critical factor in the maintenance of Treg cells suppressive function. Multiple mechanisms of action of Treg cells have been proposed, including cell contact – dependent and cytokinedependent mechanisms. However, no clear picture is available to fully elucidate the regulation of FoxP3 gene expression in Treg cells and how FoxP3-expressing Treg cells mediate the immune response in vivo. This review will discuss the research advancements in Treg cell biology including the transcription factors and signaling pathways involved in the expression of FoxP3 gene as well as the advancements in the understanding of the factors involved in the Treg cell-mediated suppressive mechanisms.
Keywords: cell differentiation, FoxP3, immune regulation, Regulatory T cells, signal transduction, Activation-induced cell death, Activator protein, Antigen presenting cells, Activating transcription factor, B cell lymphoma/leukemia 10, CARD-containing MAGUK protein 1
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: The Regulation of FoxP3-Expressing Regulatory T Cells
Volume: 11 Issue: 4
Author(s): Rizwanul Haque, Fengyang Lei, Xiaofang Xiong and Jianxun Song
Affiliation:
Keywords: cell differentiation, FoxP3, immune regulation, Regulatory T cells, signal transduction, Activation-induced cell death, Activator protein, Antigen presenting cells, Activating transcription factor, B cell lymphoma/leukemia 10, CARD-containing MAGUK protein 1
Abstract: Regulatory T (Treg) cells play an important role in the maintenance of self-tolerance and are involved in the prevention of autoimmune diseases and reduce/inhibit the progression of chronic inflammatory diseases. Forkhead box P3 (FoxP3) expression in Treg cells is believed to be a critical factor in the maintenance of Treg cells suppressive function. Multiple mechanisms of action of Treg cells have been proposed, including cell contact – dependent and cytokinedependent mechanisms. However, no clear picture is available to fully elucidate the regulation of FoxP3 gene expression in Treg cells and how FoxP3-expressing Treg cells mediate the immune response in vivo. This review will discuss the research advancements in Treg cell biology including the transcription factors and signaling pathways involved in the expression of FoxP3 gene as well as the advancements in the understanding of the factors involved in the Treg cell-mediated suppressive mechanisms.
Export Options
About this article
Cite this article as:
Haque Rizwanul, Lei Fengyang, Xiong Xiaofang and Song Jianxun, The Regulation of FoxP3-Expressing Regulatory T Cells, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (4) . https://dx.doi.org/10.2174/187153011797881157
DOI https://dx.doi.org/10.2174/187153011797881157 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology Regulation of Death and Growth Signals at the Plasma Membrane by Sphingomyelin Synthesis: Implications for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)
Current Cancer Drug Targets Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials Targeting the Resistance of Pancreatic Cancer Cells to Nutrient Deprivation: Anti-Austerity Compounds
Current Drug Delivery Monoclonal Antibodies in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews MtDNA As a Cancer Marker: A Finally Closed Chapter?
Current Genomics What is the Best Option to Cure Patients with Resistant/Relapsing Hodgkins Disease?
Current Stem Cell Research & Therapy LPTS: A Novel Tumor Suppressor Gene and a Promising Drug Target for Cancer Intervention
Recent Patents on Anti-Cancer Drug Discovery Bladder Cancer: A Simple Model Becomes Complex
Current Genomics Removal of the Tag from His-tagged ILYd4, a Human CD59 Inhibitor, Significantly Improves its Physical Properties and its Activity
Current Pharmaceutical Design Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics
Current Medicinal Chemistry Editorial (Thematic Issue: The Urgent Need to Reform the Present System of Medicines’ Regulation)
Reviews on Recent Clinical Trials Novel Chemotherapeutic Agents - The Contribution of Scorpionates
Current Medicinal Chemistry Cross Talks Between Oncoprotein Signaling Networks and Tumor Suppressor p53 in Breast Cancer
Current Cancer Therapy Reviews Radiation and Gene Therapy: Rays of Hope for the New Millennium?
Current Gene Therapy Recent Advances in Molecular Modeling and Medicinal Chemistry Aspects of Phospho-Glycoprotein&#
Current Drug Metabolism